A collaborative research group led by Professor Yasunari Miyazaki of the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University has announced that the lysoteam-chitosan oligosaccharide complex (LYZOX®) has become a problem with MRSA and resistant bacteria. It was revealed for the first time in the world that it is effective.
Improper use of antibiotics leads to resistance of bacteria, resulting in an increase in resistant bacteria, which has become a major problem these days. It is estimated that 2050 million people will die from infections caused by resistant bacteria annually in 1000, and there is a strong desire to develop new antibiotics while preventing inappropriate use of antibiotics.
The collaborative research group focused on the Maillard reaction, a reaction that combines proteins and sugars to form a complex, which enhances the antibacterial activity of the complex, and is a complex of lysoteam and chitosan, which is one of the antibacterial substances. Was prepared by the Maillard reaction.When we investigated whether the obtained lysozyme-chitosan oligosaccharide complex (LYZOX®) was effective against MRSA, Pseudomonas aeruginosa, which is a problem with drug resistance, and Acinetobacter, LYZOX® showed strong antibacterial activity against each bacterium. , It was found that the growth of bacteria was significantly suppressed by its constituents alone and the lysozyme-galactomannan complex.
Since the effect of LYZOX® was proved by this result, it is expected to be applied as a new therapeutic agent.In addition, although many antibiotics against resistant bacteria are expensive, lysozyme and chitosan oligosaccharides can be purified at a relatively low cost compared to natural materials, which may contribute to reduction of medical costs.
